Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
(FGFR2) on genetic susceptibility for breast cancer.(BC) in Chinese populations.
|
27461607 |
2017 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
FGFR2 rs2981575 had the strongest association with breast cancer risk (per allele HR = 1.28, 95% CI 1.18-1.39, ).
|
21060860 |
2010 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
FGFR2 has been identified as a breast cancer susceptibility gene.
|
26431494 |
2015 |
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Fibroblast growth factor receptor 2 (FGFR2) is overexpressed in breast cancer tissues and cells, and has been shown to be a susceptibility factor for breast cancer.
|
28132898 |
2017 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer.
|
29104507 |
2017 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
A breast cancer cell line developed in our laboratory, SUM-52PE, was shown to have a 12-fold amplification of the FGFR2 gene, and FGFR2 message was found to be overexpressed 40-fold in SUM-52PE cells as compared with normal human mammary epithelial (HME) cells.
|
11056689 |
2000 |
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
A breast cancer cell line developed in our laboratory (SUM-52PE) has a 12-fold amplification and high-level overexpression of the oncogene fibroblast growth factor receptor 2 (FGFR2).
|
15561780 |
2004 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
A combined analysis of genome-wide association studies in breast cancer.
|
20872241 |
2011 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A dose-dependent association was observed between the risk of breast cancer and the genetic risk score, which was an aggregate measure of alleles in seven selected variants, namely FGFR2-rs2981579, TOX3/TNRC9-rs3803662, C6orf97-rs2046210, 8q24-rs13281615, SLC4A7-rs4973768, LSP1-rs38137198, and CASP8-rs10931936.
|
22160591 |
2012 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
A genome-wide association study identifies a genetic variant in the SIAH2 locus associated with hormonal receptor-positive breast cancer in Japanese.
|
22951594 |
2012 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age.
|
24493630 |
2014 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1).
|
19330030 |
2009 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
A plausible functional basis for a few loci, such as FGFR2 for breast cancer and MSMB for prostate cancer, has been elucidated, but the majority are not understood and suggest new mechanisms of carcinogenesis.
|
20418093 |
2010 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A role for FOXA1 in mediating breast cancer susceptibility at this locus is consistent with the finding that the FGFR2 risk locus primarily predisposes to estrogen-receptor-positive disease.
|
24290378 |
2013 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A three-stage genome-wide association study recently identified single nucleotide polymorphisms (SNPs) in five loci (fibroblast growth receptor 2 (FGFR2), trinucleotide repeat containing 9 (TNRC9), mitogen-activated protein kinase 3 K1 (MAP3K1), 8q24, and lymphocyte-specific protein 1 (LSP1)) associated with breast cancer risk.
|
18437204 |
2008 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A variant mapping to 10q26.13, approximately 300 kb telomeric to the established risk locus within the second intron of FGFR2, was also associated with breast cancer risk, although not at genome-wide statistical significance (rs10510102: OR = 1.12, 95% CI = 1.07 to 1.17, P = 1.58 × 10(-6)).
|
21263130 |
2011 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
AA genotype and A allele of P21 and TT genotypes and T allele of FGFR2 were significantly more frequent and were associated with an increased risk of early-onset of breast cancer (95%CI: 2.54 and 1.59; 2.63 and 1.64, respectively).
|
31759353 |
2019 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer.
|
18462018 |
2008 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Although candidate gene approaches demonstrated moderately increased breast cancer risks for rare mutations in genes involved in DNA repair (ATM, CHEK2, BRIP1, PALB2 and RAD50), genome-wide association studies identified several SNPs as low-penetrance breast cancer susceptibility polymorphisms within genes as well as in chromosomal loci with no known genes (FGFR2, TOX3, LSP1, MAP3K1, TGFB1, 2q35 and 8q).
|
19092773 |
2009 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Although statistically not significant, the frequency of FGFR2 heterozygous polymorphisms in the group with breast cancer was detected to be higher.
|
24125968 |
2014 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Association analysis identifies 65 new breast cancer risk loci.
|
29059683 |
2017 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BC patients (n = 1687) randomly sampled in an adjuvant, randomized phase III trial (SUCCESS A study) were genotyped for nine BC risk SNPs: rs17468277 <i>(CASP8)</i> , rs2981582 <i>(FGFR2)</i> , rs13281615(8q24), rs3817198 <i>(LSP1)</i> , rs889312 <i>(MAP3K1)</i> , rs3803662 <i>(TOX3)</i> , rs13387042(2q35), rs4973768 <i>(SLC4A7)</i> , rs6504950 <i>(COX11)</i> .
|
28757652 |
2017 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Care must be taken when there is evidence that both the secondary trait and tested marker are associated with the primary disease, a situation we illustrate using an analysis of the relationship between a marker in FGFR2 and mammographic density in a breast cancer case-control sample.
|
19365863 |
2009 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Common genetic variants and modification of penetrance of BRCA2-associated breast cancer.
|
21060860 |
2010 |